Clinical Trials Logo

Smoking Reduction clinical trials

View clinical trials related to Smoking Reduction.

Filter by:

NCT ID: NCT04783857 Recruiting - Smoking Cessation Clinical Trials

Modifying Progesterone and Estradiol Levels to Prevent Postpartum Cigarette Smoking Relapse and Reduce Secondhand Smoke Exposure in Infants and Children

Start date: April 14, 2022
Phase: Phase 4
Study type: Interventional

The investigators aim to address the following specific aims: - Determine the efficacy of Prog in preventing postpartum smoking relapse and reducing smoking relapse risk factors. - Examine the effects of this maternal smoking intervention on infant health. - Examine racial and ethnic differences in intervention outcomes.

NCT ID: NCT04749017 Completed - Smoking Reduction Clinical Trials

The Potential Effect of Avena Sativa L. on Wellness/Wellbeing During Smoking Reduction/Cessation Experience

SMOK
Start date: January 20, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the potential effect of Avena Sativa L. on wellbeing during smoking reduction/cessation

NCT ID: NCT04620915 Recruiting - Cancer Clinical Trials

Construal Level as a Novel Pathway for Affect Regulation and Cancer Control

Start date: October 11, 2021
Phase: N/A
Study type: Interventional

The objective of the proposed research is to conduct a longitudinal experiment on the neurocognitive pathways and individual differences in high-level construal for affect regulation and smoking cessation. The population is adult smokers aged 25-55 who have tried and failed to quit and who are experiencing poverty. The primary endpoints are (a) the similarity in neural representation of high-level construal to one of two candidate pathways, (b) the presence of meaningful individual differences in the neural representation of high-level construal, and (c) as a secondary endpoint, the effect size of the high-level construal condition on smoking as measured by cigarettes per day. Each of these endpoints corresponds to a specific null hypothesis. The null hypothesis for the first endpoint is that high-level construal is not significantly different in its neural representation from down-regulation of craving, which would suggest that high-level construal does not operate through distinct mechanisms from traditional treatments. The null hypothesis for the second endpoint is that the between-subjects variability in the neural representation of construal level does not significantly relate to relevant individual differences measures (e.g., traits, task behavior), which would suggest that individual differences are not meaningfully related to outcomes. Finally, the null hypothesis for the secondary endpoint is that the magnitude of the effect of high-level construal on smoking as measured by reductions in average cigarettes per day is not significantly greater than in the other conditions, which would suggest that the efficacy of the high-level construal condition is not significantly greater than a standard text-messaging intervention. The primary endpoints will be assessed at baseline and change from pre-to-post training (8 weeks).

NCT ID: NCT04572126 Completed - Substance Use Clinical Trials

Feasibility and Efficacy of a Brief Mindfulness-Based Intervention SMOKING INTERVENTION VIA THE INTERNET

Start date: November 25, 2020
Phase: N/A
Study type: Interventional

The current study will examine both the feasibility and efficacy of a single session, web-based mindfulness-based intervention for smoking cessation. The study will explore (1) participants' subjective experiences of the intervention, (2) cravings and negative affect both before and after the intervention, and (3) changes in tobacco use one week and one month following the initial intervention. Further, the study will examine how often participants utilize the intervention between the initial study and follow-up periods.

NCT ID: NCT04271371 Completed - Smoking Clinical Trials

Preventing Relapse to Smoking Among Prisoners After Release

PROSPER
Start date: August 8, 2019
Phase:
Study type: Observational

Prisoners experience huge health inequalities, and their exceptionally high smoking prevalence (five times the national average) contributes significantly to their high mortality. Since the introduction of smoke-free polices across Her Majesty's Prison and Probation Service (HMPPS) in England and Wales, prisoners are now obliged to abstain from smoking while held in prison. This represents a unique opportunity to promote lifelong cessation in this highly disadvantaged and marginalised group. However, evidence suggests most prisoners intend to resume smoking as soon as possible after release. A systematic review of prison smoke-free polices worldwide concluded that there was a need for new research to identify effective strategies to reduce relapse in these individuals.

NCT ID: NCT04133064 Completed - Smoking Cessation Clinical Trials

Assessment of the Pivot Breath Sensor: Single-Arm Cohort Study

Start date: September 25, 2019
Phase: N/A
Study type: Interventional

Prospective open label, single center study enrolling up to 220 participants to evaluate the effect of the Pivot Breath Sensor on a user's attitudes towards quitting smoking and smoking behavior.

NCT ID: NCT03612804 Completed - Lung Diseases Clinical Trials

Promoting Smoking Cessation in Lung Cancer Screening Through Proactive Treatment

PROACT
Start date: May 10, 2019
Phase: N/A
Study type: Interventional

This pragmatic trial will evaluate the value of routinely providing proactive smoking cessation support to current smokers as a part of participating in lung cancer screening within Veterans Health Administration.

NCT ID: NCT03083353 Completed - Smoking Cessation Clinical Trials

Isradipine Enhancement of Virtual Reality Cue Exposure for Smoking Cessation

Start date: January 22, 2020
Phase: Early Phase 1
Study type: Interventional

The proposed study represents a crucial and important stage in translating basic research to strategies for treating nicotine dependence. The investigation addresses an important public health issue by testing an intervention - informed by basic research - that may lead to a more effective and efficient treatment for smokers. The expected findings should provide initial effect size data for the addition of isradipine to an integrated psychosocial/behavioral and pharmacological smoking cessation intervention for smokers, and thus provide the necessary data for a large-scale follow-up trial.